<span class='italic'>Mycobacterium ulcerans</span> Disease (Buruli Ulcer)

doi:10.1017/9781009052733.038

Chapter 37 - Mycobacterium ulcerans Disease (Buruli Ulcer)

from Section 5 - Bacterial Infections

Published online by Cambridge University Press: 18 June 2025

Richard Odame Phillips and

Edited by

Dorothy Yeboah-Manu ,

Michael Marks and

David Mabey: Affiliation:
London School of Hygiene and Tropical Medicine
Martin W. Weber: Affiliation:
World Health Organization
Moffat Nyirenda: Affiliation:
London School of Hygiene and Tropical Medicine
Dorothy Yeboah-Manu: Affiliation:
Noguchi Memorial Institute for Medical Research, University of Ghana
Jackson Orem: Affiliation:
Uganda Cancer Institute, Kampala
Laura Benjamin: Affiliation:
University College London
Michael Marks: Affiliation:
London School of Hygiene and Tropical Medicine
Nicholas A. Feasey: Affiliation:
Liverpool School of Tropical Medicine

Book contents

Get access

Summary

Buruli ulcer (BU) caused by Mycobacterium ulcerans causes a severe necrotizing infection of the skin and subcutaneous tissues. It can sometimes extend to involve the underlying muscles and rarely affects bone resulting in osteomyelitis. The disease was first described by Sir Albert Cook during his pioneering work in Uganda in 1897. Subsequently, MacCallum and other Australian scientists coincidentally found the causative organism to be M. ulcerans when an incubator originally set at 37°C broke down. The name Buruli comes from an area of Uganda where many cases were reported in the 1960s. In 1998, the World Health Organization (WHO) established the Global Buruli Ulcer Initiative to coordinate control and research activities towards the elimination of BU and this has led to major gains in understanding the disease mechanism. Now, the WHO has designated the disease as a neglected tropical disease (NTD) (WHO 2024).

Information

Type: Chapter
Information: Principles of Medicine in Africa , pp. 421 - 428

DOI: https://doi.org/10.1017/9781009052733.038 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Adusumilli, S., Mve-Obiang, A., Sparer, T. et al. 2005. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol, 7, 1295–304.CrossRef Google Scholar PubMed

Amoako, Y. A., Frimpong, M., Awuah, D. O. et al. 2019. Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports. J Med Case Rep, 13, 218.10.1186/s13256-019-2144-2CrossRef Google Scholar PubMed

Amoako, Y. A., Ackam, N., Omuojine, J. P. et al. 2021a. Caregiver burden in Buruli ulcer disease: evidence from Ghana. PLoS Negl Trop Dis, 15, e0009454.CrossRef Google Scholar PubMed

Amoako, Y. A., Loglo, A. D., Frimpong, M. et al. 2021b. Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana. BMC Infect Dis, 21, 331.10.1186/s12879-021-06009-7CrossRef Google Scholar PubMed

Amofah, G. K., Sagoe-Moses, C., Adjei-Acquah, C. & Frimpong, E. H. 1993. Epidemiology of Buruli ulcer in Amansie West district, Ghana. Trans R Soc Trop Med Hyg, 87, 644–5.10.1016/0035-9203(93)90272-RCrossRef Google Scholar

Barogui, Y. T., Klis, S. A., Johnson, R. C. et al. 2016. Genetic susceptibility and predictors of paradoxical reactions in Buruli ulcer. PLoS Negl Trop Dis, 10, e0004594.CrossRef Google Scholar PubMed

Bratschi, M. W., Bolz, M., Minyem, J. C. et al. 2013. Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl Trop Dis, 7, e2252.10.1371/journal.pntd.0002252CrossRef Google Scholar

Christinet, V., Comte, E., Ciaffi, L. et al. 2014. Impact of human immunodeficiency virus on the severity of Buruli ulcer disease: results of a retrospective study in Cameroon. Open Forum Infect Dis, 1, ofu021.CrossRef Google Scholar PubMed

De Zeeuw, J., Omansen, T. F., Douwstra, M. et al. 2014. Persisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin. PLoS Negl Trop Dis, 8, e3303.10.1371/journal.pntd.0003303CrossRef Google Scholar PubMed

Diaz, D., Döbeli, H., Yeboah-Manu, D. et al. 2006. Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol, 13, 1314–21.CrossRef Google Scholar PubMed

Frimpong, M., Sarpong-Duah, M., Beissner, M. et al. 2015. Microscopy for acid fast bacilli: a useful but neglected tool in routine laboratory diagnosis of Buruli ulcer. J Trop Dis Public Health, 3, 1–4.Google Scholar

Frimpong, M., Agbavor, B., Duah, M. S. et al. 2019a. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: relationship to bacterial load. PLoS Negl Trop Dis, 13, e0007689.10.1371/journal.pntd.0007689CrossRef Google Scholar PubMed

Frimpong, M., Ahor, H. S., Wahed, A. A. E. et al. 2019b. Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay. PLoS Negl Trop Dis, 13, e0007155.10.1371/journal.pntd.0007155CrossRef Google Scholar PubMed

Grietens, K. P., Boock, A. U., Peeters, H. et al. 2008. “It is me who endures but my family that suffers”: social isolation as a consequence of the household cost burden of Buruli ulcer free of charge hospital treatment. PLoS Negl Trop Dis, 2, e321.CrossRef Google Scholar PubMed

Guarner, J., Bartlett, J., Whitney, E. A. et al. 2003. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis, 9, 651–6.10.3201/eid0906.020485CrossRef Google Scholar PubMed

Hayman, J. 1985. Clinical features of Mycobacterium ulcerans infection. Australas J Dermatol, 26, 67-73.10.1111/j.1440-0960.1985.tb01819.xCrossRef Google Scholar PubMed

Herbinger, K. H., Adjei, O., Awua-Boateng, N. Y. et al. 2009. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis, 48, 1055–64.10.1086/597398CrossRef Google Scholar PubMed

Huang, G. K. & Johnson, P. D. 2014. Epidemiology and management of Buruli ulcer. Expert Rev Anti Infect Ther, 12, 855–65.10.1586/14787210.2014.910113CrossRef Google Scholar PubMed

Kiiza, A. M. & Wood, P. B. 2012. Buruli ulcer in an 18-day-old baby. Trop Doct, 42, 48.Google Scholar

Klis, S., Stienstra, Y., Phillips, R. O. et al. 2014. Long term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of participants in the BURULICO drug trial. PLoS Negl Trop Dis, 8, e2739.10.1371/journal.pntd.0002739CrossRef Google Scholar PubMed

Loftus, M. J., Trubiano, J. A., Tay, E. L. et al. 2018. The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia – remains similar despite changing geographic distribution of disease. PLoS Negl Trop Dis, 12, e0006323.10.1371/journal.pntd.0006323CrossRef Google Scholar PubMed

Nienhuis, W. A., Stienstra, Y., Abass, K. M. et al. 2012. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis, 54, 519–26.10.1093/cid/cir856CrossRef Google Scholar PubMed

O’Brien, D. P., Robson, M., Friedman, N. D. et al. 2013. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis, 13, 416.10.1186/1471-2334-13-416CrossRef Google Scholar PubMed

Phillips, R. O., Robert, J., Abass, K. M. et al. 2020. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet, 395, 1259–67.Google Scholar PubMed

Phillips, R. O., Sarfo, F. S., Abass, M. K. et al. 2014. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother, 58, 1161–6.10.1128/AAC.02453-14CrossRef Google Scholar PubMed

Ruf, M. T., Chauty, A., Adeye, A. et al. 2011. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis, 5, e1252.CrossRef Google Scholar PubMed

Sarfo, F. S., Phillips, R., Asiedu, K. et al. 2010. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother, 54, 3678–85.10.1128/AAC.00299-10CrossRef Google Scholar PubMed

Sarfo, F. S., Phillips, R., Wansbrough-Jones, M. & Simmonds, R. E. 2016. Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol, 18, 17–29.Google Scholar PubMed

Sarfo, F. S., Phillips, R. O., Zhang, J. et al. 2014. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis, 14, 202.Google Scholar

Sarpong-Duah, M., Frimpong, M., Beissner, M. et al. 2017. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay. PLoS Negl Trop Dis, 11, e0005695.10.1371/journal.pntd.0005695CrossRef Google Scholar PubMed

Stinear, T. P., Mve-Obiang, A., Small, P. L. et al. 2004. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA, 101, 1345–9.CrossRef Google Scholar PubMed

Trubiano, J. A., Lavender, C. J., Fyfe, J. A. et al. 2013. The incubation period of Buruli ulcer (Mycobacterium ulcerans infection). PLoS Negl Trop Dis, 7, e2463.10.1371/journal.pntd.0002463CrossRef Google Scholar PubMed

Tuffour, J., Owusu-Mireku, E., Ruf, M. T. et al. 2015. Challenges associated with management of Buruli ulcer/human immunodeficiency virus coinfection in a treatment center in Ghana: a case series study. Am J Trop Med Hyg, 93, 216–23.CrossRef Google Scholar

Wanda, F., Nkemenang, P., Ehounou, G. et al. 2014. Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection. BMC Infect Dis, 14, 423.10.1186/1471-2334-14-423CrossRef Google Scholar PubMed

WHO. 2024. www.who.int/health-topics/buruli-ulcer#tab=tab_1.Google Scholar

Yeboah-Manu, D., Röltgen, K., Opare, W. et al. 2012. Sero-epidemiology as a tool to screen populations for exposure to Mycobacterium ulcerans. PLoS Negl Trop Dis, 6, e1460.CrossRef Google Scholar PubMed

Yeboah-Manu, D., Kpeli, G. S., Ruf, M. T. et al. 2013. Secondary bacterial infections of Buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis, 7, e2191.10.1371/journal.pntd.0002191CrossRef Google Scholar PubMed

Yerramilli, A., Tay, E. L., Stewardson, A. J. et al. 2017. The location of Australian Buruli ulcer lesions – implications for unravelling disease transmission. PLoS Negl Trop Dis, 11, e0005800.10.1371/journal.pntd.0005800CrossRef Google Scholar PubMed

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.